- Home
- GROY vs AVIR Comparison
GROY vs AVIR Comparison
Compare GROY & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- AVIR
- Stock Information
- Founded
- GROY 2020
- AVIR 2012
- Country
- GROY Canada
- AVIR United States
- Employees
- GROY N/A
- AVIR N/A
- Industry
- GROY
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- GROY
- AVIR Health Care
- Exchange
- GROY Nasdaq
- AVIR Nasdaq
- Market Cap
- GROY 206.6M
- AVIR 247.5M
- IPO Year
- GROY 2021
- AVIR 2020
- Fundamental
- Price
- GROY $1.20
- AVIR $3.29
- Analyst Decision
- GROY Strong Buy
- AVIR Hold
- Analyst Count
- GROY 4
- AVIR 1
- Target Price
- GROY $3.25
- AVIR $6.88
- AVG Volume (30 Days)
- GROY 996.4K
- AVIR 491.5K
- Earning Date
- GROY 11-04-2024
- AVIR 11-07-2024
- Dividend Yield
- GROY N/A
- AVIR N/A
- EPS Growth
- GROY N/A
- AVIR N/A
- EPS
- GROY N/A
- AVIR N/A
- Revenue
- GROY $7,764,000.00
- AVIR N/A
- Revenue This Year
- GROY $289.17
- AVIR N/A
- Revenue Next Year
- GROY $102.86
- AVIR N/A
- P/E Ratio
- GROY N/A
- AVIR N/A
- Revenue Growth
- GROY 197.02
- AVIR N/A
- 52 Week Low
- GROY $1.17
- AVIR $2.75
- 52 Week High
- GROY $2.21
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- GROY 36.60
- AVIR 49.07
- Support Level
- GROY $1.17
- AVIR $3.10
- Resistance Level
- GROY $1.33
- AVIR $3.27
- Average True Range (ATR)
- GROY 0.04
- AVIR 0.16
- MACD
- GROY -0.00
- AVIR 0.02
- Stochastic Oscillator
- GROY 12.50
- AVIR 55.28
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and streaming company. It offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).